Date
- (-) 2020 (61)
- 2026 (5)
- 2025 (26)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2019 (126)
- 2018 (40)
- 2017 (21)
- 2016 (22)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (11)
- 2008 (5)
- 2007 (12)
- 2006 (10)
- 2005 (12)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (11)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (19)
Sponsor content
61 result(s) found, displaying 41 to 50
-
Prescription medicine decision summaryTGA decision: Fluzone High-Dose Quadrivalent (influenza virus haemagglutinin) is approved for influenza immunisation.
-
Prescription medicine registrationActive ingredients: influenza virus haemagglutinin.
-
Prescription medicine registrationActive ingredients: cemiplimab.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: diphtheria toxoid; pertactin; pertussis filamentous haemagglutinin; pertussis fimbriae 2 + 3; pertussis toxoid; poliovirus; tetanus toxoid.